signal transducer and activator of transcription 6Genealiases: D12S1644 · HIES6 · IL-4-STAT · STAT6B · STAT6C
Q-omics provides the consensus-scored STAT6 profile across patient tissues and cancer cell-line models. STAT6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, STAT6 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, STAT6 protein abundance shows 22,121 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where STAT6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAT6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAT6 survival associations across molecular data types. STAT6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAT6 RNA expression–survival associations across cancer types. High STAT6 expression shows unfavorable associations in UVM, LGG and HNSC, but favorable associations in MESO, THCA and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for STAT6 RNA expression.
This table summarizes STAT6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STAT6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAT6 shows lower tumor expression in UCEC, LUAD and BLCA and higher tumor expression in KIRC, KIRP and COAD. The KIRC box plot shows higher STAT6 RNA expression in tumor versus normal tissue (log2 FC = +0.587, t-test p < 0.001).
This table shows molecular features associated with STAT6 in patient tissues and cancer cell lines. In patient samples, STAT6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STAT6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
